CRVO revenueQ3 2026$0
- Quarter YoY
- -100.0%
- FY YoY
- -58.9%
CRVO revenue was $0 in fiscal Q3 2026 (ended Sep 30, 2026), down 100.0% from a year earlier. For the full fiscal 2025 it was $4.01M, down 58.9% from fiscal 2024.
CervoMed Inc. (CRVO) financials
For the twelve months ended Sep 30, 2026, CervoMed Inc. reported $8.7K of revenue and -$28.52M of net income.
- Revenue, TTM
- $8.7K
- Revenue growth, YoY
- -99.9%
- Net income, TTM
- -$28.52M
- Net margin
- -326822.5%
- Cash
- $6.06M
- P/S
- 2930.01
- Market cap
- $25.6M
FY2022FY2025
FY2016FY2025
FY2016FY2017
CRVO revenue and earnings growth
CRVO net incomeQ3 2026-$5.90M
CRVO net income was -$5.90M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$7.73M a year earlier. For the full fiscal 2025 it was -$26.97M, compared with -$16.29M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.01M | $9.74M | $7.14M | $0 | - | - | - | - | - | - |
| Research and development | $21.82M | $18.80M | $8.44M | $1.34M | $8.50M | $9.43M | $6.62M | $5.75M | $5.09M | $7.25M |
| Selling, general and admin | $10.48M | $9.17M | $6.52M | $2.14M | $7.45M | $6.44M | $4.83M | $6.17M | $6.19M | $11.09M |
| Operating income | -$28.29M | -$18.23M | -$7.81M | -$3.48M | -$24.68M | -$15.97M | -$11.55M | -$18.96M | -$11.35M | -$18.37M |
| Interest expense | - | - | $0 | $587 | - | - | - | $3.0K | $100.0K | $37.0K |
| Pre-tax income | - | - | - | -$15.59M | -$24.54M | -$15.86M | -$11.47M | -$18.81M | -$2.42M | -$18.40M |
| Income tax | $0 | - | - | $0 | -$443.9K | -$1.68M | $332.9K | -$437.3K | -$1.06M | -$364.8K |
| Net income | -$26.97M | -$16.29M | -$2.17M | -$5.80M | -$24.10M | -$14.19M | -$11.80M | -$18.37M | -$1.36M | -$18.04M |
| EPS, basic | -$2.98 | -$2.02 | -$0.82 | -$11.20 | -$12.38 | -$0.30 | -$1.76 | -$8.21 | -$3.16 | -$26.40 |
| EPS, diluted | - | - | - | $2038891.00 | $1946859.00 | $53831973.00 | $6706509.00 | $3242301.00 | -$29.11 | -$26.40 |
| Diluted shares | - | - | - | - | - | - | - | 3.2M | 848,090 | 682,186.067 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $8.24M | $9.00M | $7.79M | $4.09M | $6.67M | $18.52M | $14.18M | $7.99M | $8.90M | $1.55M |
| Short-term investments | $12.63M | $29.92M | $0 | $12.41M | $0 | - | - | - | - | - |
| Current assets | $22.88M | $43.08M | $9.96M | $4.16M | $37.82M | $18.78M | $14.65M | $8.91M | $9.67M | $1.60M |
| Goodwill | - | - | - | - | - | - | - | $0 | $6.93M | $6.93M |
| Total assets | $22.88M | $43.08M | $9.97M | $4.16M | $37.84M | $27.73M | $24.11M | $18.20M | $26.15M | $17.48M |
| Current liabilities | $4.66M | $3.88M | - | - | $2.93M | $2.44M | $1.72M | $804.0K | $2.69M | $4.44M |
| Long-term debt | - | - | - | - | - | - | - | - | - | $550.0K |
| Total debt | - | - | - | - | - | - | - | - | - | $550.0K |
| Total liabilities | $4.66M | $3.88M | $2.60M | $13.16M | $2.93M | $2.92M | $3.98M | $2.59M | $4.92M | $8.30M |
| Shareholders' equity | $18.22M | $39.20M | $7.38M | -$33.29M | -$27.94M | $24.81M | $20.13M | $15.61M | $21.23M | $9.18M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$23.45M | -$16.53M | -$7.45M | -$2.57M | -$14.50M | -$13.55M | -$9.86M | -$10.77M | -$12.33M | -$10.77M |
| Capital expenditures | - | - | - | - | - | - | - | - | $447.8K | $2.3K |
| Free cash flow | - | - | - | - | - | - | - | - | -$12.78M | -$10.77M |
| Investing cash flow | $18.10M | -$28.66M | $0 | -$12.24M | $4.0K | $0 | - | - | -$447.8K | $8.50M |
| Financing cash flow | $4.59M | $46.40M | $11.15M | $0 | $33.30M | $17.89M | $16.04M | $9.87M | $20.12M | $1.83M |
| Stock-based compensation | $1.45M | $1.41M | $407.6K | $333.8K | $897.3K | $736.1K | $515.8K | $1.22M | $1.24M | $1.39M |
| Depreciation and amortization | - | - | - | $0 | $93.4K | $103.2K | - | - | - | - |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -58.9% | 36.3% | - | - | - | - | - | - | - | - |
| Operating margin | -706.2% | -187.2% | -109.3% | - | - | - | - | - | - | - |
| Net margin | -673.1% | -167.3% | -30.4% | - | - | - | - | - | - | - |
| Return on equity | -148.0% | -41.6% | -29.4% | - | - | -57.2% | -58.6% | -117.7% | -6.4% | -196.4% |
| Return on assets | -117.9% | -37.8% | -21.8% | -139.6% | -63.7% | -51.2% | -48.9% | -100.9% | -5.2% | -103.2% |
| Current ratio | 4.91 | 11.11 | - | - | 12.92 | 7.71 | 8.51 | 11.09 | 3.59 | 0.36 |
| Debt to equity | - | - | - | - | - | - | - | - | - | 0.06 |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $8.7K | $322.6K | $1.76M | $1.92M | $2.16M | $1.94M | $3.29M | $2.35M | $2.49M |
| Research and development | $3.68M | $4.32M | $5.14M | $5.83M | $6.04M | $5.11M | $4.84M | $7.09M | $5.13M | $3.77M | $2.81M | $2.86M |
| Selling, general and admin | $2.43M | $2.36M | $2.98M | $2.51M | $2.33M | $3.27M | $2.38M | $2.32M | $2.21M | $2.51M | $2.13M | $2.12M |
| Operating income | -$6.10M | -$6.68M | -$8.11M | -$8.33M | -$8.04M | -$6.62M | -$5.30M | -$7.24M | -$5.40M | -$3.00M | -$2.59M | -$2.48M |
| Net income | -$5.90M | -$6.57M | -$7.96M | -$8.09M | -$7.73M | -$6.26M | -$4.89M | -$6.71M | -$4.75M | -$2.32M | -$2.51M | -$2.36M |
| EPS, basic | -$0.39 | -$0.64 | -$0.86 | - | -$0.84 | -$0.70 | -$0.56 | - | -$0.55 | -$0.27 | -$0.41 | - |
| EPS, diluted | - | - | - | - | - | - | - | - | -$0.55 | - | - | - |
| Diluted shares | - | - | - | - | - | - | - | - | 8.7M | - | - | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $6.06M | $22.46M | $7.94M | $8.24M | $9.44M | $8.32M | $10.50M | $9.00M | $7.74M | $10.01M | $6.37M | $7.79M |
| Short-term investments | $13.54M | $2.48M | $4.98M | $12.63M | $17.86M | $25.21M | $24.74M | $29.92M | $38.91M | $35.08M | - | $0 |
| Current assets | $21.33M | $25.99M | $15.11M | $22.88M | $30.61M | $38.08M | $38.58M | $43.08M | $48.81M | $47.33M | $7.97M | $9.96M |
| Total assets | $21.33M | $25.99M | $15.11M | $22.88M | $30.61M | $38.08M | $38.58M | $43.08M | $48.88M | $53.19M | $8.00M | $9.97M |
| Current liabilities | $3.97M | - | - | $4.66M | - | - | - | $3.88M | - | - | - | - |
| Total liabilities | $3.97M | $3.03M | $4.50M | $4.66M | $4.60M | $4.64M | $3.94M | $3.88M | $3.25M | $3.21M | $2.66M | $2.60M |
| Shareholders' equity | $17.36M | $22.96M | $10.62M | $18.22M | $26.01M | $33.44M | $34.63M | $39.20M | $45.64M | $49.98M | $5.34M | $7.38M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.07M | -$6.92M | -$8.02M | -$6.58M | -$6.47M | -$6.51M | -$3.89M | -$8.05M | -$4.85M | -$2.20M | -$1.42M | -$2.54M |
| Investing cash flow | -$10.97M | $2.53M | $7.71M | $5.37M | $7.58M | -$255.0K | $5.40M | $9.31M | $2.60M | -$40.57M | $0 | $0 |
| Financing cash flow | -$357.9K | $18.91M | $13.8K | $0 | $0 | $4.59M | $0 | $0 | -$13.3K | - | - | -$93.4K |
| Stock-based compensation | $307.4K | $362.3K | $349.2K | $298.7K | $291.7K | $497.0K | $361.2K | $337.7K | $271.2K | $578.6K | $218.2K | $165.0K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -100.0% | -100.0% | -100.0% | -99.6% | -83.4% | -46.6% | -18.3% | -13.2% | 27.1% | 91.2% | 66.7% | - |
| Operating margin | - | - | - | -95479.2% | -2493.8% | -376.4% | -276.6% | -334.9% | -278.2% | -91.1% | -110.6% | -99.6% |
| Net margin | - | - | - | -92680.4% | -2395.3% | -356.1% | -255.2% | -310.2% | -245.1% | -70.4% | -107.1% | -94.9% |
| Current ratio | 5.37 | - | - | 4.91 | - | - | - | 11.11 | - | - | - | - |
Source: XBRL data CervoMed Inc. files with the SEC, latest filing dated Nov 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-15, first reported Mar 19, 2019.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
CRVO peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CRVO | $8.7K | -99.9% | -$28.52M | -326822.5% | $25.6M |
| ANVS | $0 | - | -$51.72M | - | $59.5M |
| AVXL | - | - | -$13.02M | - | $86.2M |
| ABOS | - | - | -$103.96M | - | $15.1M |
| ALZN | - | - | -$9.10M | - | $6.0M |
CRVO FAQ
6 questionsWhat is CRVO revenue?
CervoMed Inc. (CRVO) reported $8.7K of revenue for the twelve months ended Sep 30, 2026. That is down 99.9% from the year before. Revenue for fiscal 2025 was $4.01M.Is CRVO profitable?
No. CervoMed Inc. reported a net loss of $28.52M for the twelve months ended Sep 30, 2026.How much cash and debt does CRVO have?
CervoMed Inc. reported $6.06M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is CRVO revenue growing?
CervoMed Inc.'s revenue changed -58.9% in fiscal 2025, to $4.01M.When did CRVO last report financial results?
The latest statements here come from CervoMed Inc.'s 10-Q filed on Nov 6, 2026, covering the period ended Sep 30, 2026.Where does this CRVO financial data come from?
Quantisnow builds these statements from the structured XBRL data CervoMed Inc. files with the SEC. It is provided for information only and is not investment advice.